BioVie (BIVI) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on November 10, 2026, with voting on director elections, auditor ratification, and an amendment to the equity incentive plan.

• Shareholders of record as of September 21, 2026, are eligible to vote on the proposals.

• The Board recommends voting in favor of all proposals and director nominees.

Voting matters and shareholder proposals

• Proposals include electing six directors, ratifying EisnerAmper LLP as auditor for FY 2027, and amending the 2019 Omnibus Equity Incentive Plan to increase available shares from 399,509 to 3,100,000.

• Voting is conducted online, by phone, or by mail, with detailed instructions provided.

• Shareholders may submit proposals and nominations for the 2027 annual meeting between August 12 and September 11, 2027.

Board of directors and corporate governance

• The Board consists of six members, all current directors, with a mix of industry, finance, and scientific expertise.

• Five directors are considered independent under Nasdaq standards.

• The Board has Audit, Compensation, and Nominating and Corporate Governance Committees, each composed solely of independent directors.

• The Board held eight meetings in FY 2026, with high attendance.

• A Code of Conduct and Ethics is in place, accessible on the company website.